We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Dozy do

14 December 2016 By Neil Unmack

The French firm is mooted as a buyer for the Swiss biotech group after J&J walked away. The financial logic looks equally strained, and overpaying would smack of desperation about Sanofi’s own business. With drug prices under pressure, pharma M&A will not get any more rational.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)